AbbVie Pays Capsida $70M to Expand Gene Therapy Alliance to Eye Diseases
AbbVie and Capsida Therapeutics are expanding their gene therapy R&D alliance to the eyes. Capsida is in line to receive $70 million now and up to $595 million later, depending on the progress of the eye programs.